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Abstract
Background: Failure to sustain knowledge translation (KT) interventions impacts patients and health systems,
diminishing confidence in future implementation. Sustaining KT interventions used to implement chronic disease
management (CDM) interventions is of critical importance given the proportion of older adults with chronic diseases
and their need for ongoing care. Our objectives are to (1) complete a systematic review and network meta-analysis of
the effectiveness and cost-effectiveness of sustainability of KT interventions that target CDM for end-users including
older patients, clinicians, public health officials, health services managers and policy-makers on health care outcomes
beyond 1 year after implementation or the termination of initial project funding and (2) use the results of this review
to complete an economic analysis of the interventions identified to be effective.
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Methods: For objective 1, comprehensive searches of relevant electronic databases (e.g. MEDLINE, EMBASE,
Cochrane Central Register of Controlled Trials), websites of health care provider organisations and funding
agencies will be conducted. We will include randomised controlled trials (RCTs) examining the impact of a KT
intervention targeting CDM in adults aged 65 years and older. To examine cost, economic studies (e.g. cost,
cost-effectiveness analyses) will be included. Our primary outcome will be the sustainability of the delivery of
the KT intervention beyond 1 year after implementation or termination of study funding. Secondary outcomes
will include behaviour changes at the level of the patient (e.g. symptom management) and clinician (e.g.
physician test ordering) and health system (e.g. cost, hospital admissions). Article screening, data abstraction
and risk of bias assessment will be completed independently by two reviewers. Using established methods, if
the assumption of transitivity is valid and the evidence forms a connected network, Bayesian random-effects
pairwise and network meta-analysis will be conducted. For objective 2, we will build a decision analytic
model comparing effective interventions to estimate an incremental cost-effectiveness ratio.
Discussion: Our results will inform knowledge users (e.g. patients, clinicians, policy-makers) regarding the sustainability
of KT interventions for CDM. Dissemination plan of our results will be tailored to end-users and include passive (e.
g. publications, website posting) and interactive (e.g. knowledge exchange events with stakeholders) strategies.
Systematic review registration: PROSPERO CRD42018084810
Keywords: Sustainability, Knowledge translation, Chronic disease management, Older adults, Integrated
knowledge translation
Background
The failure to successfully sustain clinical interventions
once implemented is a substantial global challenge with
research waste estimated at > $200 billion per year [1],
resulting in a need for relevant knowledge translation
(KT) science (i.e. how to optimise research use in health
care) and practice (i.e. implementing evidence in health
care) to enhance return on research investments [2]. To
optimise research impact and strengthen our health sys-
tem, we need solutions (i.e. KT science) to the critical
issue of how to sustain effective implementation (i.e. KT
practice). Sustainability was identified as one of the most
significant problems of our time, and failure to address
it threatens health care globally [3].
To illustrate the issue, we consider older adults admitted
to acute care hospitals: RCTs [4–6] show early mobilisation
decreased their length of stay and improved their health.
Early mobilisation is the clinical intervention; next, we need
a tailored KT intervention (a strategy that facilitates re-
search uptake in practice and policy) to implement it in
hospitals; the KT interventions may target individuals (e.g.
clinician audit and feedback, patient education) and organi-
sations (e.g. policy for task shifting mobility to volunteers).
Sixty-three Ontario hospitals used KT interventions [7] to
implement an early mobilisation programme over 3 years
and showed benefit; but, once effective KT interventions
are in place, how do we sustain (and adapt) them? Despite
a successful KT intervention, there is a tendency to return
to old practices after initial KT activities end and attention
and resources are turned to the next clinical issue [2]. Not
only will this impact the KT intervention sustainability but
it will also impact behaviour changes and health outcomes
in patients; anyone who has tried to start exercising, quit
smoking or lose weight knows how difficult it is to maintain
their behaviour change, which may lead to negative health
effects. Even if implementation has a small benefit, sus-
tained implementation can have a major impact on patient
outcomes over the long-term. Thus, failure to sustain KT
interventions has implications for cost and patient care and
diminishes confidence and support for future KT [8, 9].
While there is no uniform definition of KT sustainability
[3], we define it as after a defined period of time, clinical
and KT interventions continue to be delivered; clinician,
patient, organisation behaviour change is maintained; and
clinical and KT interventions may adapt, while continuing
to produce benefits for individuals and systems [10].
Our overarcwhing research goal, identified by our
knowledge users (e.g. clinicians, managers, patients, re-
searchers), is to sustain implementation of effective clin-
ical interventions through sustainable KT interventions
to optimise care of older adults with chronic diseases.
Adults aged ≥ 65 years are the largest growing propor-
tion of our population and at increased risk of develop-
ing multiple chronic diseases (e.g. heart disease,
dementia), translating to increased functional limita-
tions, hospital admission and costs [11, 12]. There are
safe and cost-effective chronic disease management
(CDM) clinical interventions, but fewer than half of eli-
gible patients receive them and significantly fewer sus-
tain use (e.g. cardiac and osteoporosis treatment) [13],
indicating a critical target for sustained KT interventions
to optimise CDM. Indeed, given the proportion of older
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adults with chronic conditions and the expected
growth in this population, KT interventions (targeting
patients, clinicians, systems) offer solutions but often
ignore real-world complexity (e.g. context and critical
health determinants such as income, literacy and gen-
der) and potential sustainability [3]. Our scoping re-
view [14] of sustainability of CDM interventions
identified 62 studies (> 260,000 patients) of 13 KT in-
terventions (e.g. clinician reminders, patient motiv-
ational interviewing), indicating need for a systematic
review and network meta-analysis (NMA; allowing
comparison of multiple interventions and producing a
ranked order of effectiveness using evidence from a
network of trials). A NMA would identify effective
and promising KT interventions among all available
options. Furthermore, we did not include any eco-
nomic studies in our scoping review [14]. To meet
these challenges, our objectives are to (1) complete a
systematic review and NMA of the comparative effect-
iveness and cost-effectiveness of sustainability of KT
interventions that target CDM for end-users including
older patients, clinicians, public health officials, health
services managers and policy-makers on health care
outcomes beyond 1 year or the termination of initial
funding and (2) use the results of this review to
complete an economic analysis of the interventions
identified to be effective. Thus, we will identify strat-
egies to assess and optimise sustainability of KT inter-
ventions for CDM in older adults, informing KT
researchers and knowledge users about how to sustain
implementation, by answering the question: What is
the comparative effectiveness and cost-effectiveness of
sustainability of knowledge translation interventions
for chronic disease management in older adults?
Methods/design
Knowledge user engagement
Knowledge users, including patients, health care managers,
policy-makers, KT researchers and KT practitioners are on
the study team. The knowledge users have provided input
into the research question and protocol and will be engaged
throughout the research enterprise through monthly updates
and quarterly webinars to discuss progress. The knowledge
users have links to broad networks of potential collaborators
who will be engaged around dissemination of the research
results. We will assess stakeholder engagement through
completion of the Patient and Public Engagement Question-
naire at study end, which has good construct validity (Dr.
Ainsley Moore, personal communication).
Objective 1
Protocol
A protocol for our systematic review was developed using
the Preferred Reporting Items for Systematic Reviews and
Meta-analyses Protocols (PRISMA-P) [15] to guide the
reporting of the systematic review protocol (see Add-
itional file 1). We registered the protocol with the PROS-
PERO database (CRD42018084810) [16].
Eligibility criteria
We will include randomised controlled trials (RCTs) with a
comparator group examining the impact of a KT interven-
tion targeting CDM in older adults after more than 1 year
of implementation or after the termination of research/pro-
ject funding is described. To examine cost, all economic
studies (e.g. cost studies with a relevant comparator,
cost-effectiveness analyses) will be included.
The target population for the CDM intervention includes
patients (aged 65 years and older with one or more chronic
disease including noncommunicable diseases) [17] or their
caregiver. End-users of the KT intervention will include pa-
tients aged 65 years and older with one or more chronic
disease, their caregivers, clinicians (from all disciplines),
public health officials (including medical officers of health,
department chairs, programme managers), health care
managers and policy-makers (including regional, state/pro-
vincial, federal).
The CDM intervention is the clinical intervention
such as use of exercise in a patient with type 2 diabetes;
the KT intervention is the strategy used to support im-
plementation of the CDM intervention, such as a re-
minder system for patients to exercise or motivational
interviewing for clinicians to promote patient exercise.
CDM interventions may target any chronic condition
and may target the patient, caregiver, clinician or health
system, with a goal to optimise health and well-being of
the patient. All comparators are eligible for inclusion in-
cluding other KT interventions or usual care.
Our primary outcome will be sustained implementa-
tion of the KT intervention beyond 1 year after imple-
mentation or the termination of funding as this was
determined by our knowledge users to be relevant for
decision-making in their contexts. Additionally, as sec-
ondary outcomes, we will consider sustained delivery of
the CDM interventions as well of any patient (e.g. qual-
ity of life), clinician (e.g. eye examination frequency) or
health care system (e.g. hospital admission) outcomes
resulting from sustained behaviour change. Studies in all
settings will be eligible, including primary and specialist
care; acute and long-term care; inpatient and outpatient
care; and regional, national, and international settings.
Both published and unpublished material will be in-
cluded, as well as those disseminated in any language.
Charting and outcome selection
The outcomes and outcome measures reported in all
identified studies will be charted in Excel. All knowledge
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users (patients, clinicians, health care managers, policy-
makers) on the team will then review this list and select
the outcomes that are most relevant for their
decision-making. We will aim to identify equal numbers
of participants from each KU group, and in the case
of non-response KUs will be asked to nominate an
individual to replace them on the panel. Specifically, a
modified Delphi approach [18] commonly used in
quality improvement research [19] with two rounds
will be used to achieve consensus on what KT and
patient, clinician and health system outcomes should
be considered for inclusion. First, an online survey
using Qualtrics [20] will be sent to the knowledge
users, which will include the list of outcomes, their
definitions, and the frequency with which they ap-
peared in the studies. The knowledge users will be
invited to rate the importance of each outcome on a
7-point Likert scale ranging from ‘not at all import-
ant’ to ‘extremely important’. Second, their ratings
will be aggregated and median ratings will be calcu-
lated. Outcomes with median ratings of ≥ 5 and ap-
propriate levels of agreement among KUs (e.g. ≥ 75%
of ratings must fall within three points of the median
score) will be considered important outcomes and will
be included in the second round. Third, in the second
round, the knowledge users will assess the shortened
list of preferred outcomes and will be asked to rank
their top 3 outcomes. This process will be used to identify
the primary and secondary outcomes by selecting the
three outcomes with the highest ranking.
Information sources
We will conduct a systematic search of the published and
difficult to locate or unpublished (i.e. grey) literature within
health. Health will be defined using the World Health
Organization (WHO) definition [21]. The following elec-
tronic databases will be searched from inception onwards:
MEDLINE, EMBASE, Cochrane Central Register of Con-
trolled Trials, Cumulative Index to Nursing and Allied
Health Literature (CINAHL) and Campbell databases.
A search of the grey literature will be conducted
using a strategically developed Google search strategy,
using guidance from the Canadian Agency for Drugs
and Technologies in Health Grey Matters tool [22].
We will search the websites of key funding agencies
(e.g. Canadian Institutes of Health Research) and health
care provider organisations from Australia, Canada, the
UK and the USA who have similar health care systems
or similar challenges related to CDM. References from
included studies and relevant articles will be scanned to
ensure literature saturation. Team members will use
their linkages with experts in the field to identify add-
itional articles.
Search strategy
The main (i.e. MEDLINE) search strategy was developed
by an experienced librarian, circulated to the team and
revised, as necessary. The search used for our previous
scoping review on this same topic was used as the basis
for this search [23]; however, it was substantially modi-
fied to include various categorisations of potential KT
interventions including the Effective Practice and Organ-
isation of Care (EPOC) taxonomy of health systems
interventions [24]. The search was organised according
to the research question and PICO and included both
MeSH and keyword terms for chronic medical diseases,
specific MeSH and keyword terms for EPOC-related
concepts and concepts related to knowledge translation
and sustainability. The search was limited to humans
and validated filters were used for older adults and ran-
domised trials [25].
The search for the current review was then peer
reviewed by a second experienced librarian using the
Peer Review of Electronic Search Strategies (PRESS)
Checklist [26]. The final search strategy can be found
in Additional file 2. The search was adjusted and trans-
lated for other databases, as necessary, and these other
search strategies are available from the authors upon
reasonable request.
Study selection
The eligibility criteria will be pilot-tested on a random
sample of 50 titles and abstracts from the literature search.
All team members will screen these citations using the eli-
gibility criteria independently and conflicts will be dis-
cussed. The eligibility criteria will be revised if deemed
necessary by the team or if low agreement (< 90%) is ob-
served. Two team members will then screen each citation
independently using Synthesi.SR [27]. Similarly, we will
conduct a calibration exercise of the eligibility criteria
prior to screening potentially relevant full-text articles,
which will then be screened by two team members inde-
pendently. At both the citation and full-text levels of
screening, conflicts will be resolved via discussion among
pairs or reviewers or with a third member, if required.
Data items and data collection process
Two investigators will independently read each article and
extract relevant data when available. We will abstract data
at the following levels:
1. Study level: study design, year of study conduct,
sample size, setting, country of study conduct, study
funding source and KT theory/model/framework
used to inform study
2. Patient level: type and number of patients, age
mean and standard deviation, proportion of female
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participants, type of chronic condition(s) and
number of clusters
3. Intervention level: type (e.g. KT interventions will
be classified using a behaviour change techniques
taxonomy) [28], frequency and duration of CDM
and KT interventions, provider and target
4. Outcome level: patient, clinical and health system
including cost-effectiveness (e.g. incremental cost-
effectiveness ratios (ICERs) cost per quality adjusted
life year (QALY))
Prior to data abstraction, we will calibrate our data
collection form on a random sample of five full-text arti-
cles. Each team member will extract the data, and the
team will meet to discuss conflicts. The data collection
form will be revised for clarity, as needed. Subsequently,
two team members will conduct all data collection for
each study independently. Study authors will be con-
tacted for further information as needed when consider-
ing studies for inclusion and when conducting data
abstraction. When multiple studies report data from the
same study population, the study with the longest
follow-up and available data will be considered the main
publication and the others will be retained for supple-
mentary material only.
Two reviewers with expertise in KT and research
methods will independently code each KT intervention
first using the pre-existing taxonomy developed by the
Cochrane EPOC group and then a behaviour change
technique taxonomy to identify the specific active com-
ponents in each intervention [24, 28]. Conflicts in KT
intervention coding will be resolved through discussion.
We will use this coding structure to create the nodes for
the NMA by ‘lumping’ interventions according to the
taxonomy categories and have used this approach in
other NMAs of complex interventions [29].
Methodological quality/risk of bias appraisal
Two reviewers will conduct risk of bias independently
on each included study. If there is disagreement, a third
reviewer will be available. The risk of bias of RCTs will
be done using the Cochrane EPOC Risk of Bias tool
[30], and cost-effectiveness analysis studies will be eval-
uated against the reporting checklist developed by
Drummond and colleagues [31]. For outcomes reported
in 10 or more studies, small-study effects (e.g., publica-
tion bias) will be assessed using comparison-adjusted
funnel plots [32].
Synthesis of included studies
We will describe the study characteristics, patient char-
acteristics, outcome results, the methodological quality
and risk of bias. We will report the results using the
PRISMA extension for NMAs [33].
We anticipate clinical and methodological heterogen-
eity and thus will conduct random-effects meta-analysis
in a Bayesian framework. We will assess heterogeneity of
the included studies in terms of clinical (e.g. patient
characteristics), methodological (e.g. study design) and
statistical (e.g. heterogeneity in study outcomes between
studies) characteristics. For example, clinicians on the
team will assess clinical heterogeneity and methodolo-
gists will assess study heterogeneity. Statistical hetero-
geneity will be assessed by visual inspection of each
meta-analysis forest plot, by estimating the between-
study variance and by using the I2 statistic [25, 34]. If ex-
tensive heterogeneity is observed, we will try to explain
this via sub-group analysis and meta-regression analysis
[35].We will use vague priors for all model parameters
aside from the between-study variance for which we will
use the informative priors suggested by Turner and
colleagues for dichotomous data and by Rhodes and col-
leagues for continuous data [36, 37]. In each NMA, we
will assume a common within-network between-study
variance across treatment comparisons and we will use
an informative prior as suggested in Turner et al. [36],
Rhodes et al. [37] and Nikolakopoulou et al. [38].
Multi-arm studies will be included in a head-to-head
meta-analysis using the exact adjustment method as de-
scribed by Rucker et al. [39]. The meta-regression ana-
lyses will be conducted when 10 or more studies are
available for the underlying outcome and intervention
comparison and will examine the influence of factors
such as age and severity of chronic disease and risk of
bias on the meta-analysis results.
For continuous outcomes, to make use of all data, we
will impute missing measures of variance using estab-
lished methods [40]. To ensure our imputations do not
bias our results, we will conduct a sensitivity analysis to
examine the missing data under random, completely at
random and non-random assumptions.
The transitivity assumption will be assessed visually to
ensure that potential effect modifiers (e.g. patient age,
comorbidities) are balanced on average across compari-
sons [41]. We expect that transitivity will be valid if the
common intervention used to compare different KT in-
terventions indirectly is similar when it appears in differ-
ent trials. Consistency of the entire network will be
assessed with the design-by-treatment interaction model
[42]. If inconsistency is found within the network, the
loop-specific approach will be used to assess local incon-
sistency of the loops within each network [43]. If the as-
sumption of transitivity is valid and the evidence forms a
connected network, we will conduct a NMA using a
Bayesian random-effects model.
Across all analyses, the summary intervention effects
will be presented using the odds ratio or mean difference
with the corresponding 95% credible intervals. Predictive
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intervals will also be reported for meta-analyses and
NMA point estimates. We will assess model conver-
gence using the Gelman-Rubin diagnostic and goodness
of model fit [44] will be assessed using the posterior re-
sidual deviance, the degree of heterogeneity, and the De-
viance Information Criterion (DIC) [45]. A well-fitting
model has a residual deviance close to the number of
data points. A difference of ≥ 3 units in DIC is consid-
ered important and the lowest DIC value implies the
best fitting model. Mean ranks and the surface under
the cumulative ranking curves (SUCRAs) will be used to
derive a relative ranking of the KT interventions based
on the NMA results [46]. Rank-heat plots will be used
to display the intervention rankings across multiple out-
comes [47].
Network subgroup and meta-regression analyses will
be done to explore potential effect modifiers that impact
transitivity or consistency assumptions when ten or
more studies are available in the underlying outcome. If
there are a sufficient number of studies, we will explore
the following potential effect modifiers: sex, type of
chronic disease, cluster of diseases (as reported in the
studies such as diabetes and depression), severity of
chronic diseases, care setting, and duration of follow-up.
Sensitivity analysis will be done whereby we use data
from the following studies in the NMA: (1) studies at
low risk of bias based on the two components of our risk
of bias assessment found to be of the greatest threat to
study validity and (2) studies with high participant reten-
tion. Since the NMA is dependent on different priors for
variance parameters included in the Bayesian approach,
we will conduct a sensitivity analysis using vague priors
[48]. All analyses will be performed within OpenBUGS,
except for the consistency assessment that will be con-
ducted in Stata using the network command [49, 50]. To
ensure reproducibility, code listings or citations provid-
ing guidance on the methods employed in this NMA will
be available upon request.
Objective 2
Economic analyses
Using the findings from the systematic review and
NMA, we will identify effective and sustainable KT in-
terventions. Subsequently, we will conduct an economic
evaluation to compare the cost and outcome among
these KT interventions and use the results from the re-
view to guide the selection of perspective, cost items to
include, outcomes of interest and time horizon including
other relevant model parameters. The details on specific
data required for economic analyses will depend on the
systematic review and NMA findings. Thus, a detailed
protocol outlining the specific methods for the economic
analysis will be prepared at a later date when NMA find-
ings are available. We will conduct the analysis using the
guideline from the Canadian Agency for Drugs and
Technologies in Health [51] and based on the consoli-
dated reporting standards [52].
Discussion and dissemination
The sustainability of KT interventions is critical to en-
suring long-term, high quality of care for patients, and
this is particularly important for older adults with
chronic diseases [53]. KT interventions that are not sus-
tained represent an inefficient use of limited resources
may worsen patient outcomes and negatively impact our
health systems [13, 54]. As such, evaluating sustainability
of KT interventions is increasingly important and sus-
tainability has been identified as one of the critical gaps
in KT science [3].
Our research will be relevant to KT researchers, as
well as clinicians, patients and policy-makers. Our team
includes representatives of these various knowledge user
groups, and this will facilitate use of the research results.
Indeed, we developed this protocol in direct response to
needs identified by the knowledge users to address sus-
tainability in health care. We will ensure that knowledge
users continue to be engaged throughout the conduct of
this review and they will lead dissemination efforts for
our research results. We will use evidence-based ap-
proaches to dissemination, which will be tailored to the
end-user needs. We will use a variety of passive (e.g.
publication) and active (e.g. knowledge exchange events)
dissemination strategies. We anticipate using the results
of this review to inform the development of a toolkit for
those interested in developing sustainable KT interven-
tions for CDM in older adults.
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